Dr. Agarwal's Health Care Limited saw a reduction in its pledged shareholding after Catalyst Trusteeship Limited released encumbrance over a significant portion of its equity shares. The security agent, acting for lenders to Hyperion Investments Pte. Ltd., disclosed the release of 31,698,303 equity shares on August 11, 2026.

The disclosure was made under Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The shares were originally pledged as security for a facility agreement dated March 26, 2024, between Hyperion Investments Pte. Ltd. and certain lenders. The facility aggregated up to USD 100,000,000.

Pledge Position Update

Prior to this release, Catalyst Trusteeship held an encumbrance over 73,193,988 equity shares, which constituted 23.09% of the total share capital and 22.93% of the diluted share capital. Following the partial release, the remaining encumbered shares stand at 41,495,685.

The release of encumbrance is treated as a disposal under Regulation 29(2) read with Regulation 29(4) of the Takeover Code. No acquisition or sale of shares carrying voting rights occurred during this transaction.

What the Numbers Show

The data reveals a significant de-leveraging event within the promoter group's collateral structure. By releasing nearly 43% of the previously pledged block (31.69 million out of 73.19 million shares), the borrower has substantially reduced the security interest held by lenders. While 13.09% of the voting capital remains encumbered, the reduction from a 23.09% pledge level indicates improved liquidity or debt repayment capacity relative to the initial facility terms established in March 2024.

Dr. Agarwal's Health Care reported a 44.6% year-on-year surge in consolidated net profit after tax (PAT) to ₹55.02 crore for Q1FY27, driven by robust revenue growth of 26% to ₹614.02 crore. The eye care chain strengthened its operational footing by expanding its network to 304 facilities across 10 countries and executing its largest-ever quarterly expansion of surgical centers. Standalone PAT also grew significantly to ₹16.67 crore from ₹10.11 crore in the same period last year, reflecting improved operating leverage and significant growth in high-margin specialized procedures.

Q1FY27 Financial Performance

The Board of Directors, meeting on August 04, 2026, approved unaudited financial results showing significant top-line and bottom-line improvements across both standalone and consolidated structures. Consolidated revenue from operations grew to ₹614.02 crore from ₹487.42 crore in Q1FY26. Total income rose 23.9% to ₹620.43 crore. Consolidated EBITDA increased by 25.2% to ₹176.82 crore, with margins widening to 28.5% from 28.2%.

Standalone revenue from operations stood at ₹382.62 crore, up from ₹301.72 crore in Q1FY26. Standalone EBITDA reached ₹98.99 crore, compared to ₹79.83 crore previously. Profit after tax (PAT) climbed to ₹16.67 crore from ₹10.11 crore, with PAT margins expanding to 4.4% from 3.3%.

Operational Expansion and Network Growth

As of June 30, 2026, the company’s network expanded to 304 facilities, adding 18 new facilities during the quarter while closing two primary centers in Janipur (Jammu) and Zirakpur (Punjab). This included a record 16 new surgical facilities. The company performed 91,082 surgeries, a 15.5% year-on-year increase from 78,882 in Q1FY26. Cataract surgeries accounted for 67,444 procedures, while refractive surgeries grew to 3,998. The company served over 8.8 lakh patients with a team of 1,057 doctors. CEO Dr. Adil Agarwal highlighted that greenfield losses were contained despite launching 23 surgical facilities in the preceding six months.

Specialized surgical procedures showed strong momentum:

• Femto Cataracts: 1,548 procedures (33.4% YoY growth)
• Lenticular Procedures: 1,712 procedures (36.2% YoY growth)
• Retinal Surgeries: 3,861 procedures (30.0% YoY growth)
• Anterior Segment Reconstruction: 286 procedures (15.8% YoY growth)
• Corneal Transplants: 589 procedures (10.1% YoY growth)

Corporate Governance and Strategic Moves

The Board appointed M/s. S.R. Batliboi & Associates LLP as Statutory Auditors until the conclusion of the 20th AGM, filling a casual vacancy left by Deloitte Haskins & Sells. M/s. KPMG Assurance and Consulting Services LLP was appointed as Internal Auditors for FY2026-27, replacing M/s. R.G.N Price & Co., which had served for seven years. B Y & Associates was re-appointed as Cost Auditors for FY2026-27.

Strategically, the company proposed incorporating a wholly owned subsidiary in Nigeria through its Mauritius entity, Orbit Healthcare Services. The Nigerian entity will engage in comprehensive eye care services subject to regulatory approvals from bodies including the Corporate Affairs Commission (CAC) and Medical and Dental Council of Nigeria (MDCN).

Regarding capital utilization, the Board approved the reallocation of ₹14.88 crore of surplus funds from "IPO expenses" to "General Corporate Purposes" in May 2026. As of June 30, 2026, ₹17.69 crore of fresh issue proceeds remained unutilized, invested in fixed deposits. Additionally, IdeaRx Services Private Limited ceased to be an associate entity effective March 30, 2026, following the termination of shareholder rights under the shareholders' agreement, though the company retains a 14.54% equity stake.

What the Numbers Show

The divergence between revenue growth (26%) and EBITDA growth (25.2%) alongside margin expansion indicates effective operating leverage. The significant rise in consolidated PAT (44.6%) outpacing EBITDA growth suggests favorable tax dynamics or lower interest expenses relative to earnings. The growth in specialized high-margin procedures like Femto Cataracts and Retinal Surgeries supports the margin expansion narrative, demonstrating successful clinical innovation adoption across the network.